Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial

Pascal Roullet, Guillaume Vaiva, Etienne Véry, Axel Bourcier, Antoine Yrondi, Laetitia Dupuch, Pierre Lamy, Claire Thalamas, Laurence Jasse, Wissam El Hage, Philippe Birmes, Pascal Roullet, Guillaume Vaiva, Etienne Véry, Axel Bourcier, Antoine Yrondi, Laetitia Dupuch, Pierre Lamy, Claire Thalamas, Laurence Jasse, Wissam El Hage, Philippe Birmes

Abstract

Post-traumatic stress disorder (PTSD) is difficult to treat but one promising strategy is to block memory reconsolidation of the traumatic event. This study aimed to evaluate the efficacy of traumatic memory reactivation under the influence of propranolol, a noradrenergic beta-receptor blocker, in reducing PTSD symptoms as well as comorbid major depression (MD) symptoms. We conducted a double blind, placebo-controlled, randomised clinical trial in 66 adults diagnosed with longstanding PTSD. Propranolol or a placebo was administered 90 min before a brief memory reactivation session, once a week for 6 consecutive weeks. Measures included the SCID PTSD module, the PTSD Check List (PCL-S) and the Beck Depression Inventory-II (BDI-II). PTSD symptoms decreased both in the pre-reactivation propranolol group (39.28%) and the pre-reactivation placebo group (34.48 %). During the 6 treatment sessions, PCL-S and BDI-II scores decreased to similar extent in both groups and there were no treatment differences. During the 3-month follow-up period, there were no treatment effects for the mean PCL-S and BDI-II scores. However, in patients with severe PTSD symptoms (PCL-S ≥ 65) before treatment, PCL-S and BDI-II scores continued to decline 3 months after the end of treatment in the propranolol group while they increased in the placebo group. Repeated traumatic memory reactivation seemed to be effective for PTSD and comorbid MD symptoms. However, the efficacy of propranolol was not greater than that of placebo 1 week post treatment. Furthermore, in this traumatic memory reactivation, PTSD symptom severity at baseline might have influenced the post-treatment effect of propranolol.

Trial registration: ClinicalTrials.gov NCT01713556.

© 2021. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Figures

Fig. 1. Participant flow diagram.
Fig. 1. Participant flow diagram.
Eligible participants were randomly assigned to group treatments (propranolol = “traumatic memory reactivation + propranolol” group; placebo = “traumatic memory reactivation + placebo” group). Four patients did not meet the inclusion criteria (no PTSD n = 1 and PCL-S < 45 at W1 n = 3). W week.
Fig. 2. Change in PTSD and MD…
Fig. 2. Change in PTSD and MD symptoms during the treatment period.
A Mean PCL-S score. 33 patients attended the first treatment session and 29 during week 7 for both groups. B Change in MD symptoms during the treatment period. PCL-S = PTSD Checklist; BDI-II = the Beck Depression Inventory-II, propranolol = “traumatic memory reactivation + propranolol” group; placebo = “traumatic memory reactivation + placebo” group.
Fig. 3. Change in PTSD and MD…
Fig. 3. Change in PTSD and MD symptoms based on initial PTSD severity before treatment.
A Change in PTSD symptoms during the treatment period depending on the initial level of PTSD (mean PCL-S score), B change in MD symptoms during the treatment period depending on the initial level of PTSD (mean PCL-S score). Propranolol = “traumatic memory reactivation + propranolol” group; Placebo = “traumatic memory reactivation + placebo” group. *p < 0.05, **p < 0.01.

References

    1. Yin Q, Sun Z, Liu T, Ni X, Deng X, Jia Y, et al. Posttraumatic stress symptoms of health care workers during the corona virus disease 2019. Clin. Psychol. Psychother. 10.1002/cpp.2477(2020).
    1. Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, et al., Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study. Brain Behav Immun. 10.1016/j.bbi.2020.05.038(2020).
    1. Tran K, Moulton K, Santesso N, Rabb D, CADTH Health Technology Assessments, Cognitive processing therapy for post-traumatic stress disorder: a systematic review and meta-analysis. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2016.
    1. Kline AC, Cooper AA, Rytwinksi NK, Feeny NC. Long-term efficacy of psychotherapy for posttraumatic stress disorder: a meta-analysis of randomized controlled trials. Clin Psychol Rev. 2018;59:30–40. doi: 10.1016/j.cpr.2017.10.009.
    1. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD) Int J Neuropsychopharmacol. 2012;15:825–40. doi: 10.1017/S1461145711001209.
    1. Asnis GM, Kohn SR, Henderson M, Brown NL. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs. 2004;64:383–404. doi: 10.2165/00003495-200464040-00004.
    1. Krystal JH, Davis LL, Neylan TC, M AR, Schnurr PP, Stein MB, et al. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD Psychopharmacology Working Group. Biol Psychiatry. 2017;82:e51–e59. doi: 10.1016/j.biopsych.2017.03.007.
    1. Przybyslawski J, Roullet P, Sara SJ. Attenuation of emotional and nonemotional memories after their reactivation: role of beta adrenergic receptors. J Neurosci. 1999;19:6623–8. doi: 10.1523/JNEUROSCI.19-15-06623.1999.
    1. Sara SJ. Retrieval and reconsolidation: toward a neurobiology of remembering. Learn Mem. 2000;7:73–84.
    1. Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature. 2000;406:722–6. doi: 10.1038/35021052.
    1. Brunet A, Poundja J, Tremblay J, Bui E, Thomas E, Orr SP, et al. Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. J Clin Psychopharmacol. 2011;31:547–50. doi: 10.1097/JCP.0b013e318222f360.
    1. Debiec J, Bush DE, LeDoux JE. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats-a possible mechanism for the persistence of traumatic memories in PTSD. Depression Anxiety. 2011;28:186–93. doi: 10.1002/da.20803.
    1. Strawn JR, Geracioti TD., Jr Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depression Anxiety. 2008;25:260–71. doi: 10.1002/da.20292.
    1. Villain H, Benkahoul A, Drougard A, Lafragette M, Muzotte E, Pech S, et al. Effects of propranolol, a beta-noradrenergic antagonist, on memory consolidation and reconsolidation in mice. Front Behav Neurosci. 2016;10:49. doi: 10.3389/fnbeh.2016.00049.
    1. Kindt M, Soeter M, Vervliet B. Beyond extinction: erasing human fear responses and preventing the return of fear. Nat Neurosci. 2009;12:256–8. doi: 10.1038/nn.2271.
    1. Lonergan MH, Olivera-Figueroa LA, Pitman RK, Brunet A. Propranolol’s effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: a meta-analysis. J psychiatry Neurosci. 2013;38:222–31. doi: 10.1503/jpn.120111.
    1. Lonergan M, Saumier D, Tremblay J, Kieffer B, Brown TG, Brunet A. Reactivating addiction-related memories under propranolol to reduce craving: a pilot randomized controlled trial. J Behav Ther Exp Psychiatry. 2016;50:245–9. doi: 10.1016/j.jbtep.2015.09.012.
    1. Soeter M, Kindt M. An abrupt transformation of phobic behavior after a post-retrieval amnesic agent. Biol Psychiatry. 2015;78:880–6. doi: 10.1016/j.biopsych.2015.04.006.
    1. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008;42:503–6. doi: 10.1016/j.jpsychires.2007.05.006.
    1. Brunet A, Ashbaugh AR, Saumier D, Nelson M, Pitman RK, Tremblay J, et al. Does reconsolidation occur in humans: a reply. Front Behav Neurosci. 2011;5:74. doi: 10.3389/fnbeh.2011.00074.
    1. Wood NE, Rosasco ML, Suris AM, Spring JD, Marin MF, Lasko NB, et al. Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies. Psychiatry Res. 2015;225:31–39. doi: 10.1016/j.psychres.2014.09.005.
    1. Brunet A, Saumier D, Liu A, Streiner DL, Tremblay J, Pitman RK. Reduction of PTSD symptoms with pre-reactivation propranolol therapy: a randomized controlled trial. Am J Psychiatry. 2018;175:427–33. doi: 10.1176/appi.ajp.2017.17050481.
    1. Estévez-Lamorte N, Pitzurra R, Foster S, Gmel G, Mohler-Kuo M, Schnyder U. Exposure to potentially traumatic events in young Swiss men: associations with socio-demographics and mental health outcomes (alcohol use disorder, major depression and suicide attempts) Eur J Psychotraumatol. 2019;10:1611093. doi: 10.1080/20008198.2019.1611093.
    1. Elhai JD, Grubaugh AL, Kashdan TB, Frueh BC. Empirical examination of a proposed refinement to DSM-IV posttraumatic stress disorder symptom criteria using the National Comorbidity Survey Replication data. J Clin Psychiatry. 2008;69:597–602. doi: 10.4088/JCP.v69n0411.
    1. El-Hage W, Birmes P, Jehel L, Ferreri F, Benoit M, Vidailhet P, et al. Improving the mental health system for trauma victims in France. Eur J Psychotraumatol. 2019;10:1617610. doi: 10.1080/20008198.2019.1617610.
    1. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV Axis I Disorders, research version, non-patient edition (SCID-I/NP). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 2002.
    1. Ventureyra VA, Yao SN, Cottraux J, Note I, De Mey-Guillard C. The validation of the Posttraumatic Stress Disorder Checklist Scale in posttraumatic stress disorder and nonclinical subjects. Psychother Psychosom. 2002;71:47–53. doi: 10.1159/000049343.
    1. First M, Spitzer R, Gibbon M. Structured clinical interview for DSMIV (Axis I Disorders): Nonpatient edition. New York, NY: Biometrics Research Department, NY State Psychiatric Institute; 1995.
    1. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Personal Assess. 1996;67:588–97. doi: 10.1207/s15327752jpa6703_13.
    1. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options, The. J Clin Psychiatry. 2002;63:826–37. doi: 10.4088/JCP.v63n0913.
    1. Mueller HS, Ayres SM. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man. J Clin Investig. 1980;65:338–46. doi: 10.1172/JCI109677.
    1. Mueller HS, Ayres SM. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man. J Clin Investig. 1980;65:338–46. doi: 10.1172/JCI109677.
    1. Hoffman BB. Cathecolamines, sympathomimetic drugs and adrenergic receptor antagonists. In: Brunton L, editor. Goodman & Gilman’s: the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001, p. 215–68.
    1. Dey M, Brisson J, Davis G, Enever R, Pray K, Zaim B, et al. Relationship between plasma propranolol concentration and dose in young, healthy volunteers. Biopharm Drug Dispos. 1986;7:103–11. doi: 10.1002/bdd.2510070202.
    1. Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005;162:214–27. doi: 10.1176/appi.ajp.162.2.214.
    1. Suzuki A, Josselyn SA, Frankland PW, Masushige S, Silva AJ, Kida S. Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J Neurosci. 2004;24:4787–95. doi: 10.1523/JNEUROSCI.5491-03.2004.
    1. Roley ME, Claycomb MA, Contractor AA, Dranger P, Armour C, Elhai JD. The relationship between rumination, PTSD, and depression symptoms. J Affect Disord. 2015;180:116–21. doi: 10.1016/j.jad.2015.04.006.
    1. Disner SG, Beevers CG, Haigh EA, Beck AT. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 2011;12:467–77. doi: 10.1038/nrn3027.
    1. Köhler CA, Carvalho AF, Alves GS, McIntyre RS, Hyphantis TN, Cammarota M. Autobiographical memory disturbances in depression: a novel therapeutic target? Neural Plast. 2015;2015:759139. doi: 10.1155/2015/759139.
    1. Geracioti TD, Jr., Baker DG, Ekhator NN, West SA, Hill KK, Bruce AB, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry. 2001;158:1227–30. doi: 10.1176/appi.ajp.158.8.1227.
    1. De Jaeger X, Courtey J, Brus M, Artinian J, Villain H, Bacquie E, et al. Characterization of spatial memory reconsolidation. Learn Mem. 2014;21:316–24. doi: 10.1101/lm.033415.113.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner